The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin

(2010) C. C. Chu et al.   BLOOD

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

PKC  is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC  as a therapeutic target in chronic lymphocytic leukemia

(2009) C. Holler et al.   BLOOD

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406

(2009) M. P. Quiroga et al.   BLOOD

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

(2009) David M. Lucas et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia

(2009) Maike Buchner et al.   CANCER RESEARCH

Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas

(2009) R. J. Bende et al.   HAEMATOLOGICA

Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia

(2009) A Sanchez-Aguilera et al.   LEUKEMIA

The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression

(2009) A D Baudot et al.   ONCOGENE

E -TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction

(2009) G. Gorgun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial

(2008) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk

(2008) A. Podolanczuk et al.   BLOOD

A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies

(2008) A. Lanemo Myhrinder et al.   BLOOD

Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA

(2008) C. C. Chu et al.   BLOOD

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target

(2008) R. M. Young et al.   BLOOD

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

(2008) S Gobessi et al.   LEUKEMIA

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

(2007) P. G. Longo et al.   BLOOD